Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04830124
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2021-04-01
Brief Title:
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Organization Data
Organization:
Mural Oncology Inc
Class:
INDUSTRY
Study ID:
ALKS 4230-006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Mural Oncology Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None